Abstract 1801P
Background
ADTi is the standard of care treatment (Rx) for mCSPC. We hypothesized that pts who received ADTi in mCSPC and progressed to mCRPC would have different disease characteristics and survival than those treated with ADT monotherapy (ADTm) in the mCSPC setting.
Methods
After IRB approval, patient (pt)-level data were collected retrospectively. Eligibility: confirmed diagnosis of mCRPC, treated with 1L approved Rx with follow up data available. Pts were stratified based on whether they received ADTi (docetaxel or novel hormonal therapies) or ADTm in the mCSPC setting. Study endpoints: Progression-free survival (PFS) as and overall survival (OS) from time of mCRPC diagnosis. A multivariate analysis using the Cox proportional hazards model was used adjusting for potential confounders.
Results
519 consecutive pts (368 ADTm and 151 ADTi) seen at our institution between 2009 to 2022 were eligible. mCRPC pts who received ADTi compared to ADTm had lower PSA (10.3 vs. 21.5 ng/ml, P = 0.002), more visceral metastases (20.5 vs. 11.1%, P = 0.005), higher alkaline phosphatase (110.5 vs. 96 U/L, P = 0.034); and had worse median PFS (5.3 vs. 8.6 months, P < 0.001) and OS (21.2 vs. 31.7 months, P < 0.001) compared to those with ADTm in both univariate and multivariate analysis (Table).
Table: 1801P
PFS HR (95% CI, P-value) | OS HR (95% CI, P-value) | |
ADT vs. ADTi (univariate) | 0.7 (0.57-0.86, P < 0.001) | 0.63 (0.49-0.8, P < 0.001) |
ADT vs. ADTi (multivariate) | 0.7 (0.53 – 0.91, P = 0.009) | 0.69 (0.50 – 0.97, P = 0.03) |
Visceral Metastasis | 0.73 (0.52 – 1.02, P = 0.062) | 0.62 (0.43 – 0.90, P = 0.012) |
Log PSA | 1.12 (1.06 – 1.18, P < 0.001) | 1.13 (1.06 – 1.21, P < 0.001) |
Hemoglobin | 0.86 (0.80 – 0.92, P < 0.001) | 0.87 (0.81 – 0.94, P < 0.001) |
Alkaline Phosphatase | 1.00 (1.00 – 1.00, P = 0.081) | 1 (1.00 – 1.00, P = 0.086) |
Gleason Score > 8 | 0.77 (0.58 – 1.01, P = 0.062) | 0.79 (0.57 – 1.09, P = 0.14) |
Conclusions
In the era of ADTi for mCSPC, the survival outcomes in the mCRPC is poorer compared to those in the era of ADTm for mCSPC. These hypothesis-generating data may aid patient counseling, prognostication, and clinical trial design in mCRPC in the current era.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B.L. Maughan: Financial Interests, Personal and Institutional, Advisory Board, paid consultant/advisor to AbbVie, Pfizer, AVEO oncology, Janssen, Astellas, BMS, Clovis, Tempus, Merck, Exelixis, Bayer Oncology and Peloton Therapeutics; Huntsman Cancer Institute has received research funding from Exelixis (Inst), Bavarian-Nordic (Inst), Clovis (Inst), Genentech (Inst) and BMS (Inst) on his behalf: paid consultant/advisor to AbbVie, Pfizer, AVEO oncology, Janssen, Astellas, BMS, Clovis, Tempus, Merck, Exelixis, Bayer Oncology and Peloton Therapeutics; Huntsman Cancer Institute has received research funding from Exelixis (Inst), Bav. N. Agarwal: Financial Interests, Personal and Institutional, Advisory Board, Consultancy to Astellas, AstraZeneca, Aveo, Bayer, BMS, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. Research funding to Neeraj Agarwal's institution: Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, BMS, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon: Consultancy to Astellas, AstraZeneca, Aveo, Bayer, BMS, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle G. U. Swami: Financial Interests, Personal and Institutional, Advisory Board, a consulting or advisory role by Seattle Genetics, Astellas Pharma, Exelixis, Imvax, and AstraZeneca, currently or during the past 2 years. Dr. Swami’s institution has received research funding from Janssen, Seattle Genetics/Astellas, and Exelixis, currently or within the past 2 years: a consulting or advisory role by Seattle Genetics, Astellas Pharma, Exelixis, Imvax, and AstraZeneca, currently or during the past 2 years. Dr. Swami’s institution has received research funding from Janssen, Seattle Genetics/Astellas, and Exelixis, curren. All other authors have declared no conflicts of interest.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1204TiP - Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Presenter: Neel Belani
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14